Dr. Seth Orlow and three panelists, Chris Chapman of Dermavant Sciences, Dr. Neal Walker of Aclaris Therapeutics, and Frank Watanabe of Arcutis Biotherapeutics, discussed the commercial prospects for topical therapies in the current environment.

Gianfranco Nazzi, Chief Executive Officer at Almirall shared his vision for the organization’s future.

Three emerging companies in the dermatology space presented in the Entrepreneurial Company Showcase. They included, Jeune a gene-based aesthetics company, NFlection Therapeutics a company developing therapies for rare diseases, and Sofregen Medical a medical device company leveraging the science of natural silk protein.

Dr. James Lee spoke about how Incyte entered the dermatology space and what is coming next for the organization’s dermatology franchise.

Dr. Jean Tang and three panelists, Dr. Mary Spellman of Castle Creek Biosciences, Dr. Mansoor Mirza of Abeona Therapeutics, and Suma Krishnan of Krystal Biotech discussed each organization’s approaches for treating Epidermolysis Bullosa and what their pivotal clinical trials could mean for the future for innovative therapies for the disease and its subtypes.

Todd Zavodnick, Chief Executive Officer at Dermavant Sciences spoke about how his organization is poised to transform immuno-dermatology.

Dr. Kristen Slaoui and three panelists, Dr. Shimon Eckhouse of Alon Medtech, Dr. Dieter Manstein of Harvard Medical School and Dr. Micah Bregman of Allergan Aesthetics discussed how consumers are shaping the facial filler industry and what to expect in terms of novel technology, trends and techniques.

Dr. Brian Kim chaired a session in which the speakers presented on their organization’s therapeutic development programs for pruritus. The speakers included Jennifer Good of Trevi Therapeutics and Dr. Jonny Finlay of Granular Therapeutics.

For additional information on this topic, we invite you to view a separate symposium hosted by Dr. Kim titled The Mast Cell-Neuron Axis: Implications for future Skin and Itch Therapies